Headache and Migraine

Allergan’s oral CGRP antagonist showed a higher likelihood of freedom from pain and associated symptoms during mild headaches for patients with migraine compared to attacks of moderate to severe severity.

The anti-CGRP agent showed sustained benefit in reducing migraine frequency as well as good safety over 4 or more years of treatment in a cohort of more than 200 patients.

The neurologist at the Barrow Neurological Institute detailed how she has gotten patients to buy into the adjustment to a virtual medical care model, and what challenges she's had to overcome.

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Neurology News Network for the week ending April 25, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.

The neurologist at the Barrow Neurological Institute discussed her experience with telemedicine and gave advice on how to conduct examinations through audio/video platforms.

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.

The professor of neurology at the University of Vermont Larner College of Medicine detailed what lessons and highlights he’s learned from shifting his migraine care to a telemedicine-based model during the COVID-19 pandemic.

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

The professor of neurology at the University of Vermont Larner College of Medicine discussed the response from payers and physicians to the special article he and colleagues published in the journal Headache.

Neurology News Network for the week ending April 18, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the special article he and colleagues published in the Headache journal on migraine care.

Migraine expert Teshamae Monteith, MD, describes how the University of Miami's inpatient migraine service has been a go-to resource for migraine help.

The CEO of Biohaven Pharmaceuticals discussed the company’s new collaboration, which has made rimegepant (Nurtec ODT) available for prescription through Cove’s telemedicine platform.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the need to get patients with migraine access to medications during the COVID-19 pandemic.

Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.

In addition to having a lowered number of headache days, around 20% of patients transformed to low-frequency, episodic migraine on follow-up.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy spoke about the impact the COVID-19 pandemic has had on his practice.

Incorporating remote electrical neuromodulation into the standard of care may have a positive impact on migraine management by reducing the reliance on acute medications.

The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.

Results from one of the first multi-case studies of neurologic manifestations of COVID-19 demonstrate complex CNS involvement and raise further questions about pathological mechanism.